Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2020 Jul;55(7):1469-1472. doi: 10.1038/s41409-019-0708-9. Epub 2019 Oct 7.

Authors

Affiliations

¹ Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. [email protected].

^# Contributed equally.

PMID: 31591448
DOI: 10.1038/s41409-019-0708-9

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific* / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Recurrence

Substances

Antibodies, Bispecific
blinatumomab